Drug Profile
Research programme: mGlu4 PAM - Addex Therapeutics
Alternative Names: ADX 88178; mGluR4 modulators - Addex Therapeutics; mGluR4 PAM; VU0003423Latest Information Update: 01 Sep 2021
Price :
$50
*
At a glance
- Originator Addex Pharmaceuticals; Merck & Co
- Developer Addex Therapeutics; Ecole Polytechnique Federale de Lausanne.; University of Lausanne
- Class Antiparkinsonians; Anxiolytics; Behavioural disorder therapies; Drug withdrawal therapies; Small molecules
- Mechanism of Action Metabotropic glutamate receptor 4 modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Parkinson's disease
- No development reported Anxiety disorders; Autistic disorder; Cocaine-related disorders; Multiple sclerosis
Most Recent Events
- 01 Sep 2021 Research programme for mGlu4 PAM is still in preclinical trials in Parkinson's disease in Switzerland (PO) (Addex Therapeutics pipeline, September 2021)
- 28 Jan 2021 No recent reports of development identified for preclinical development in Autistic-disorder in Switzerland (PO)
- 28 Nov 2020 No recent reports of development identified for preclinical development in Cocaine-related-disorders in Switzerland (PO)